NEW YORK, Sept. 20, 2018 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today
announced that the Company will participate in the Oppenheimer
& Co. Fall Summit Focused on Specialty Pharma and Rare
Disease, to be held September 26-27, 2018 in New York
City. Management will be hosting one-on-one meetings at the
conference as follows:
Date:
|
Thursday, September
27, 2018
|
Time:
|
8:00 am to 5:00 pm
(ET)
|
Location:
|
The Langham Hotel,
New York City
|
To schedule a meeting with Actinium, please contact Steve O'Loughlin, Principal Financial Officer
via email soloughlin@actiniumpharma.com or through the Oppenheimer
conference website
https://www.opco.com/conferences/nypharma18/index.aspx.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage
biopharmaceutical company focused on developing and commercializing
targeted therapies for potentially superior targeted conditioning
of the bone marrow prior to a bone marrow transplant and for the
targeting and killing of cancer cells. The Company's targeted
Antibody Radio-Conjugates (ARCs), combine the targeting ability of
monoclonal antibodies with the cell killing ability of
radioisotopes. Actinium is developing a pipeline of
clinical-stage ARCs targeting CD45 and CD33 for patients with a
broad range of hematologic malignancies.
Iomab-B, Actinium's lead product candidate, is currently
enrolling patients in a pivotal Phase 3 trial. Iomab-B combines the
anti-CD45 monoclonal antibody BC8 labeled with iodine-131 and is
designed to condition the bone marrow prior to a bone marrow
transplant without the need for intense chemotherapy in patients
with relapsed or refractory acute myeloid leukemia (AML) of age 55
or older. Actinium's pipeline also includes a potentially
best-in-class CD33 program with our ARC comprised of the anti-CD33
antibody lintuzumab labeled with the alpha-particle emitter
actinium-225. Its CD33 program is currently being studied in
Phase 2 and Phase 1 clinical trials for patients with AML,
myelodysplastic syndrome (MDS) and multiple myeloma.
Actinium is also developing its proprietary Actinium Warhead
Enabling (AWE) technology platform to utilize the highly
differentiated radioisotope actinium-225 with a wide range of
targets. AWE is being utilized in a collaborative research
partnership with Astellas Pharma, Inc.
More information is available at www.actiniumpharma.com and our
Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals,
Inc.
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on
management's current expectations and are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with preliminary study results
varying from final results, estimates of potential markets for
drugs under development, clinical trials, actions by the FDA and
other governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Principal Financial Officer
soloughlin@actiniumpharma.com
Investor Relations
Rx Communications Group
Paula Schwartz
917-322-2216
pschwartz@rxir.com
Susan A. Noonan
212-966-3650
investorrelations@actiniumpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-participate-in-the-oppenheimer--co-fall-summit-focused-on-specialty-pharma-and-rare-disease-300715908.html
SOURCE Actinium Pharmaceuticals, Inc.